Alterity Therapeutics Limited
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $84.6M
- Price
- $4.67
- % Change (Daily % change from the live per-ticker quote feed.)
- +4.94%
- Volume
- 10.6K
About
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
Quick stats
Shares outstanding18.1M
Computed float6.4M
Float / shares35.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001131343
AI Summary
AI-generated1/14
majorpress release
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
– Newly granted patent extends protection for ATH434 to at least 2045, significantly enhancing its strategic value and long-term commercial potential –